--- title: "Marketing in the Gray Zone: How to Promote Emerging Regenerative Therapies Without Overstepping FDA Lines" url: "https://marketermagazine.co/insight/marketing-in-the-gray-zone-how-to-promote-emerging-regenerative-therapies-without-overstepping-fda-lines/" author: "Seth Berge" published: "2026-09-25" updated: "2026-09-25" --- # Marketing in the Gray Zone: How to Promote Emerging Regenerative Therapies Without Overstepping FDA Lines Few categories put marketers in a tighter spot than regenerative medicine. The science behind stem cell and exosome-based therapies is genuinely advancing, patient interest is high, and the competitive pressure to differentiate is real — but the regulatory ground underneath all of it is still being defined. Most products in this space are not FDA-approved for the conditions they're commonly marketed toward, and the FDA has been increasingly active in warning companies whose marketing outpaces their evidence. For anyone building campaigns in this category, that's not a reason to avoid marketing altogether. It's a reason to get very deliberate about how. Here is what responsible, compliant marketing actually looks like in a category this early-stage. ### **Know the difference between a disease claim and a mechanism claim** This is the single most important distinction in regenerative medicine marketing, and the one companies get penalized for blurring. Describing what a therapy is and how it's believed to work — its mechanism, the biology, the research questions it's exploring — is generally on solid ground. Claiming that it treats, cures, reverses, or prevents a specific disease or condition is a drug claim, and making that claim for a product that hasn't been approved for it is exactly what draws FDA warning letters. "This therapy is being studied for its potential role in modulating inflammation" is a mechanism claim. "This therapy treats osteoarthritis" is a disease claim. The line is subtle in wording but enormous in regulatory consequence. ### **Avoid borrowing certainty from adjacent, unrelated science** A common shortcut in this category is citing legitimate stem cell or exosome research from an unrelated application, then implying it supports the product being sold. If a peer-reviewed study looked at exosomes in wound healing, it doesn't substantiate a claim about joint pain relief, even if the underlying vesicle is the same. Marketing copy should tie claims to evidence for the actual product and actual indication being marketed, not the broader promise of the science. ### **Be transparent about investigational status** Patients researching these therapies are often more sophisticated than marketers assume, and they can tell when investigational or unapproved status is being obscured. Clear language — this is not FDA-approved for this use, this is offered under X framework, here is what has and hasn't been studied — reads as credible rather than as a weakness. Hiding that status, or burying it in fine print far from the claims it qualifies, is one of the more common triggers for regulatory action and reputational damage alike. ### **Treat testimonials and before/after content carefully** Patient testimonials describing dramatic outcomes function, in the eyes of regulators, very similarly to direct efficacy claims — especially when they're the centerpiece of a campaign rather than a supplement to substantiated information. A single glowing testimonial can imply a typical result even when it isn't one. If testimonials are used, pairing them with accurate context about typical outcomes and individual variability matters more than most marketing teams assume. ### **Loop in regulatory review before campaigns go live, not after** The teams that stay out of trouble in this category build regulatory or legal review into the campaign process itself, the same way they'd build in brand or legal review for anything else. Waiting until after a claim has run in a campaign to ask whether it was substantiated is how avoidable warning letters happen. This is especially true for anything involving comparative claims, specific outcome statistics, or language implying approval status the product doesn't have. ### **Why this approach wins over time** None of this is about marketing less aggressively — it's about marketing on a foundation that can survive scrutiny. In a category this early and this scrutinized, the brands that build a reputation for careful, accurate communication tend to outlast the ones that lean on urgency and inflated claims, both because patients increasingly know the difference and because the regulatory tolerance for overstatement in this space is shrinking, not growing. Marketing that holds up to an FDA reviewer's read is, in practice, usually the same marketing that holds up to a skeptical, well-informed patient's read. Building campaigns around that overlap is the most durable strategy available in this category right now. --- Seth Berge is Founder and CEO of [Regenerative Revival](https://regenerativerevival.com).